Latest Pharma and Biotech News
Pharmaceutical
13 March 2025 Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis.
Today's issue
Refine Search
Biotechnology
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company. 16 March 2025
Biotechnology
US biotech Regenxbio has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) RGX-111 and is on track for potential US Food and Drug Administration (FDA) approval via accelerated approval in second-half 2025. 15 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. 14 March 2025
Biotechnology
Innovent Biologics has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED).
The National Medical Products Administration (NMPA) cleared the treatment, making it the second IGF-1R antibody therapy approved globally. 14 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 US flu season following a thorough and comprehensive review of US and global surveillance data. 14 March 2025
Pharmaceutical
The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a significant shift in the nation's healthcare management. The restructuring aims to cut bureaucracy and enhance efficiency, resulting in approximately 10,000 job losses, with the anticipated savings redirected to frontline services. 14 March 2025
Pharmaceutical
The UK government plans to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' National Health Service (NHS) sales in the second half of 2025. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Biotechnology
Sutro Biopharma, a US biotechnology company, has announced significant organizational changes, including a workforce reduction of nearly 50%, a shift in its drug development focus, and leadership transitions. 14 March 2025
Biotechnology
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). 14 March 2025
Pharmaceutical
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. 14 March 2025
Pharmaceutical
Japan’s Shionogi yesterday delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025 on its ensitrelvir. 14 March 2025
Pharmaceutical
Swiss drugmaker Idorsia has announced the publication of a Phase IV study in the Journal of Sleep Research. 14 March 2025
Biotechnology
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Pharmaceutical
Hours before his confirmation hearing, the Trump Administration pulled the nomination of Dr Dave Weldon to be the director of the Centers for Disease Control and Prevention (CDC). 14 March 2025
Biotechnology
Japanese drugmaker Seikagaku Corporation announced that it has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning Seikagaku’s biologics license application (BLA) for SI-6603 (condoliase), a treatment that reduces leg pain associated with lumbar disc herniation. 14 March 2025
Biotechnology
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Biotechnology
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today announced a research and license agreement with German family-owned pharma major Boehringer Ingelheim to accelerate the development of multiple drug targets. 13 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
All news
Biotechnology
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company. 16 March 2025
Biotechnology
US biotech Regenxbio has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) RGX-111 and is on track for potential US Food and Drug Administration (FDA) approval via accelerated approval in second-half 2025. 15 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. 14 March 2025
Biotechnology
Innovent Biologics has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED).
The National Medical Products Administration (NMPA) cleared the treatment, making it the second IGF-1R antibody therapy approved globally. 14 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 US flu season following a thorough and comprehensive review of US and global surveillance data. 14 March 2025
Pharmaceutical
The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a significant shift in the nation's healthcare management. The restructuring aims to cut bureaucracy and enhance efficiency, resulting in approximately 10,000 job losses, with the anticipated savings redirected to frontline services. 14 March 2025
Pharmaceutical
The UK government plans to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' National Health Service (NHS) sales in the second half of 2025. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Biotechnology
Sutro Biopharma, a US biotechnology company, has announced significant organizational changes, including a workforce reduction of nearly 50%, a shift in its drug development focus, and leadership transitions. 14 March 2025
Biotechnology
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). 14 March 2025
Pharmaceutical
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. 14 March 2025
Pharmaceutical
Japan’s Shionogi yesterday delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025 on its ensitrelvir. 14 March 2025
Pharmaceutical
Swiss drugmaker Idorsia has announced the publication of a Phase IV study in the Journal of Sleep Research. 14 March 2025
Biotechnology
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Pharmaceutical
Hours before his confirmation hearing, the Trump Administration pulled the nomination of Dr Dave Weldon to be the director of the Centers for Disease Control and Prevention (CDC). 14 March 2025
Biotechnology
Japanese drugmaker Seikagaku Corporation announced that it has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) concerning Seikagaku’s biologics license application (BLA) for SI-6603 (condoliase), a treatment that reduces leg pain associated with lumbar disc herniation. 14 March 2025
Biotechnology
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Biotechnology
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today announced a research and license agreement with German family-owned pharma major Boehringer Ingelheim to accelerate the development of multiple drug targets. 13 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze